FYR Diagnostics Inc.

Missoula, MT

UEI
FXC2KX47NS48
CAGE
8KXG5
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1121 E Broadway St, Missoula, MT 59802, USA
Website
fyr.bio
Founded
2016
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 -$55,000
FY2025 $354,828

Contract awards

Grant awards

Grant subawards

Prime recipient Prime award Amount Awarded
State Of Montana Department Of Health And Human Services Lab NU50CK000500 $5,700,000

Similar vendors

About the company

FYR Diagnostics Inc. is a for-profit corporate entity based in Missoula, Montana, specializing in medical diagnostic technologies and research focused on early disease detection. Registered in SAM.gov since April 2020, the company develops innovative diagnostic solutions primarily in the healthcare sector, with a particular emphasis on advanced molecular and genomic testing approaches. The company demonstrates expertise in developing non-invasive diagnostic tools targeting complex medical conditions, leveraging microRNA and extracellular vesicle research to create advanced screening methodologies.

FYR Diagnostics Inc. has received a significant Small Business Set Aside federal contract from the National Cancer Institute (NCI), valued at $354,828, for developing tumor-derived extracellular vesicles to diagnose early-stage ovarian cancer. This Firm Fixed Price STTR Phase I research contract is scheduled for completion by September 14, 2026, and will be performed in Missoula, Montana. The contract represents the company's capability to engage in sophisticated medical research targeting critical diagnostic challenges, specifically focusing on innovative approaches to early cancer detection through advanced molecular screening techniques.

The company has also been awarded a federal grant from the National Institute on Drug Abuse for a project addressing Neonatal Opioid Withdrawal Syndrome (NOWS). This grant, awarded on August 15, 2021, involved collaborative research with the University of New Mexico and Texas A&M University to develop a non-invasive diagnostic assay using umbilical cord samples. The project aimed to create an accessible, sensitive diagnostic tool for early detection of severe NOWS, addressing critical challenges in identifying high-risk infants exposed to opioids. Additionally, FYR Diagnostics Inc. received two sub-grant awards from the State of Montana Department of Health and Human Services in December 2020, further demonstrating its engagement in laboratory-based research and diagnostic development.

Quick answers

Is FYR Diagnostics Inc. registered in SAM.gov?

Yes. FYR Diagnostics Inc.'s SAM.gov registration is active through April 24, 2027.

How much has FYR Diagnostics Inc. received in federal contracts?

Federal contracts obligated $354,828 to FYR Diagnostics Inc. in fiscal year 2025 and $299,828 in fiscal years 2023 through 2027.

What is FYR Diagnostics Inc.'s most recent federal award?

FYR Diagnostics Inc.'s most recent federal contract award is Tumor-derived extracellular vesicles for diagnosis of early-stage ovarian cancer (75N91025C00044), from National Cancer Institute (NIH), on September 15, 2025.

On GovTribe

See FYR Diagnostics Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors